Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds
Lunai Bioworks (NASDAQ:LNAI) announced early results from an AI-driven platform that identifies compounds interacting with acetylcholinesterase (AChE), the molecular target of nerve agents. The company reported its predictive model achieved 0.94 AUROC for distinguishing active AChE inhibitors from inactive compounds and flagged previously unidentified candidate neurotoxic compounds for follow-up. Lunai plans to combine the AI predictions with behavioral zebrafish profiling to observe real-time physiological effects and prioritize countermeasures. The company also embedded the model in a partner dashboard to enable collaborative chemical-structure screening for potential neurotoxicity.
Lunai Bioworks (NASDAQ:LNAI) ha annunciato risultati preliminari provenienti da una piattaforma guidata dall'IA che identifica composti in grado di interagire con l'acetilcolinesterasi (AChE), bersaglio molecolare degli agenti nervini. L'azienda ha riferito che il suo modello predittivo ha raggiunto 0,94 AUROC nel distinguere inibitori attivi della AChE da composti inattivi e ha segnalato per ulteriori approfondimenti composti neurotossici candidati finora non identificati. Lunai prevede di combinare le previsioni AI con profilazione comportamentale in zebrafish per osservare effetti fisiologici in tempo reale e dare priorità alle contromisure. L'azienda ha anche incorporato il modello in una dashboard partner per consentire lo screening collaborativo della struttura chimica al fine di identificare potenziali neurotossicità.
Lunai Bioworks (NASDAQ:LNAI) anunció resultados preliminares de una plataforma impulsada por IA que identifica compuestos que interactúan con la acetilcolinesterasa (AChE), el objetivo molecular de los agentes nerviosos. La compañía informó que su modelo predictivo consiguió un AUROC de 0,94 para distinguir inhibidores activos de la AChE de compuestos inactivos y señaló compuestos neurotóxicos candidatos no identificados previamente para seguimiento. Lunai planea combinar las predicciones de IA con perfilado conductual en peces cebra para observar efectos fisiológicos en tiempo real y priorizar contramedidas. La compañía también integró el modelo en un panel de socios para permitir cribado colaborativo de estructuras químicas en busca de posible neurotoxicidad.
Lunai Bioworks (NASDAQ:LNAI)는 아세틸콜린에스터레이스(AChE)와 상호작용하는 화합물을 식별하는 AI 기반 플랫폼의 조기 결과를 발표했습니다. 회사는 예측 모델이 활성 AChE 억제제를 비활성 화합물과 구별하는 데 0.94 AUROC를 달성했고, 이전에 식별되지 않았던 신규 후보 신경독성 화합물을 후속 조사 대상으로 지목했다고 밝혔습니다. Lunai는 AI 예측을 제브라피시 행동 프로파일링과 결합해 실시간 생리적 효과를 관찰하고 대응책의 우선순위를 정할 계획입니다. 또한 모델을 파트너 대시보드에 포함시켜 잠재적 신경독성에 대한 협력적 화합물-구조 스크리닝을 가능하게 했습니다.
Lunai Bioworks (NASDAQ:LNAI) a annoncé des résultats préliminaires d'une plateforme pilotée par l'IA qui identifie des composés interagissant avec l'acétylcholinestérase (AChE), la cible moléculaire des agents nerveux. La société a indiqué que son modèle prédictif avait atteint 0,94 AUROC pour distinguer les inhibiteurs actifs de l'AChE des composés inactifs et a signalé des candidats neurotoxiques jusqu'alors non identifiés pour un suivi. Lunai prévoit de combiner les prédictions de l'IA avec un profilage comportemental chez le poisson-zèbre afin d'observer des effets physiologiques en temps réel et de prioriser les contre-mesures. La société a également intégré le modèle dans un tableau de bord partenaire pour permettre un criblage collaboratif de structures chimiques en vue d'une neurotoxicité potentielle.
Lunai Bioworks (NASDAQ:LNAI) kündigte frühe Ergebnisse einer KI-gesteuerten Plattform an, die Verbindungen identifiziert, die mit Acetylcholinesterase (AChE) interagieren, dem molekularen Ziel von Nervengiften. Das Unternehmen berichtete, dass sein prädiktives Modell 0,94 AUROC erreichte, um aktive AChE-Inhibitoren von inaktiven Verbindungen zu unterscheiden, und identifizierte zuvor unbekannte neurotoxische Kandidaten zur Nachverfolgung. Lunai plant, die KI-Vorhersagen mit Verhaltensprofiling von Zebrafisch zu kombinieren, um Echtzeit-physiologische Effekte zu beobachten und Gegenmaßnahmen zu priorisieren. Das Unternehmen hat das Modell auch in ein Partner-Dashboard eingebettet, um ein kollaboratives Screening von chemischen Strukturen auf potenzielle Neurotoxizität zu ermöglichen.
Lunai Bioworks (NASDAQ:LNAI) أعلنت نتائج مبكرة من منصة مدفوعة بالذكاء الاصطناعي تحدد المركبات التي تتفاعل مع إنزيم الأستيل كولين استيريز (AChE)، الهدف الجزيئي للعوامل العصبية. ذكرت الشركة أن نموذجها التنبؤي حقق 0.94 AUROC للتمييز بين مثبطات AChE النشطة والمركبات غير النشطة، وأشارت إلى مركبات نيوتوكسية عصبية لم تُعرف من قبل للمتابعة. تخطط Lunai لدمج توقعات الذكاء الاصطناعي مع تصنيف سلوكي لسمك الزرد لرصد التأثيرات الفيزيولوجية في الوقت الحقيقي وتحديد أولويات التدابير المضادة. كما أدمجت الشركة النموذج في لوحة معلومات الشريك لتمكين فحص هيكليات كيميائية تعاونيًا لاحتمالية السمية العصبية.
- Model performance reported at 0.94 AUROC
- Identified previously unknown candidate AChE inhibitors for follow-up
- Integrated predictive model into a partner dashboard for collaborative screening
- None.
Insights
Early, data-backed AI signal for acetylcholinesterase inhibition; promising for screening but validation remains essential.
Lunai reports an AI classifier that distinguishes AChE-active from inactive compounds with an AUROC of
Model performance alone does not prove biological hazard or therapeutic value; in vivo confirmation is required. The plan to combine behavioral zebrafish profiling with the predictive model addresses this gap because zebrafish assays capture whole-organism physiology not seen in biochemical screens. Key risks include dataset bias, overfitting to training sources, and false positives that could divert laboratory resources.
Watch for published validation results showing blinded in vivo confirmation rates, assay reproducibility, and the timeline for follow-up studies; expect meaningful readouts within the next several months if throughput claims hold. These metrics determine whether the platform shifts from promising proof-of-concept to an operational surveillance or screening tool.
Platform appears operationally relevant for defense/public health screening; governance and controlled access will determine practical impact.
The company embedded its predictive model in a partner-facing dashboard and identified previously unknown compounds with potential AChE activity. That workflow (predict→prioritize→validate) shortens discovery cycles and could accelerate identification of both threats and countermeasure leads if validation confirms predictions.
Dependencies include the quality and provenance of training data and access controls for a tool that flags nerve-agent–relevant activity. Responsible use measures and partner vetting are critical given dual-use concerns; the announcement emphasizes defense and public-health intent but provides no details on safeguards. Monitor disclosures about data governance, partner selection, and any external validation studies over the next
NEW YORK, NY / ACCESS Newswire / October 30, 2025 / In the face of growing global concern over the potential use of chemical weapons such as the nerve agent Sarin, Lunai Bioworks Inc. (NASDAQ:LNAI) today announced promising early results from its AI-based platform designed to identify compounds that interact with acetylcholinesterase (AChE), the same molecular target affected by nerve agents.
"This research brings us closer to a future where proactive, AI-powered screening can detect and evaluate neurotoxic compounds before they become threats," said David Weinstein, CEO of Lunai Bioworks. "Our vision is to use in vivo systems like zebrafish, combined with predictive AI, to rapidly identify neurotoxic threats and screen for countermeasures, and leverage our AI models to help safeguard against the creation of new neurotoxins."
Using a combination of chemical feature analysis and machine learning classifiers, Lunai's platform demonstrated an ability to differentiate active AChE inhibitors from inactive compounds with high accuracy (0.94 AUROC; Area Under the Receiver Operating Characteristic curve). The work builds on models trained using the company's in-house neuroactive compound screening data, as well as public sources, and applies predictive modeling to identify chemical signatures associated with AChE inhibition. Compounds with previously unidentified, potential neurotoxic activity have been identified for follow-up and validation.
Lunai's work represents a responsible application of AI, focused on defense and public health, not harm. The announcement comes amid increasing concern about the potential misuse of generative AI technologies, underscored by a recent NBC News investigation showing how AI chatbots could be manipulated to share instructions for creating dangerous substances, including nerve agents.
In future phases, the company plans to integrate its behavioral zebrafish profiling platform to observe real-time physiological effects of predicted inhibitors, helping prioritize candidate compounds for further development as potential countermeasures.
Zebrafish are an FDA-recognized model for toxicology and drug discovery, offering a unique balance of genetic relevance to humans and scalability unmatched by rodent models. Lunai's platform leverages these advantages by coupling high-throughput behavioral assays in zebrafish with machine learning models trained to recognize neurotoxic phenotypes. This approach enables rapid, low-cost screening of both suspected threat agents and potential countermeasure compounds, often identifying hits within days rather than months, a critical advantage in time-sensitive defense and public health scenarios.
To support collaboration, Lunai has embedded its predictive model into a customized dashboard, allowing partners to explore their chemical structures and determine if they have potential neurotoxicity.
About Lunai
Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats.
Forward-Looking Statements:
This press release contains "forward-looking statements" within the meaning of the Private Litigation Reform Act of 1995 regarding the plans and objectives of management for future operations and market trends and expectations. Forward-looking statements can be identified by the fact that they do not related strictly to historical or current facts. Forward-looking statements are based upon our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. In some cases, you can identify forward-looking statements by the following words: "may", "could", "would", "should", "expect", "intend", "plan", "anticipate", "believe", "approximately", "estimate", "predict", "project", "potential" or the negative of these terms or other comparable terminology, although the absence of these words does not necessarily mean that a statement is not forward-looking. A forward-looking statement is neither a prediction nor a guarantee of future events or circumstances, and those future events or circumstances may not occur. You should not place undue reliance on forward-looking statements, which speak only as of the date of this Press Release. Forward-looking statements involve known and unknown risks, uncertainties, and other factors, that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations and assumptions that involve numerous risks and uncertainties. Our plans and objectives are based, in part, on assumptions involving the continued expansion of our business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Lunai Bioworks encourages you to review the risk factors that may affect its future performance in its filings with the Securities and Exchange Commission. We are including this cautionary note to make applicable and take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additional information respecting factors that could materially affect the Company and its operations are contained in the Company's filings with the SEC which can be found on the SEC's website at www.sec.gov.
Contact:
press@lunaibioworks.com
www.lunaibioworks.com
SOURCE: Lunai Bioworks Inc.
View the original press release on ACCESS Newswire
FAQ
What accuracy did Lunai Bioworks report for its AChE inhibitor AI model (LNAI) on October 30, 2025?
How will Lunai (LNAI) use zebrafish profiling with its AI predictions?
Did Lunai (LNAI) identify new potential neurotoxic compounds?
How can partners access Lunai's (LNAI) predictive screening tools?
What is the intended purpose of Lunai's (LNAI) AI platform?
How quickly does Lunai (LNAI) say its platform can identify screening hits?
